LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Mas
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing OligonucleotidesPreclinical proof of concept for the Company’
… ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit … of ProQR will present our proprietary RNA Base Editing Axiomer ® Technology including editing efficiency in various models. “Our Axiomer ® RNA base editing platform uses the body’s own …
… ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology … ProQR to focus exclusively on the development of the Axiomer ® RNA editing technology platform across multiple … growth initiatives related to the advancement of its Axiomer RNA editing platform include both in-house …